CFT8634, a Clinical Stage BRD9 Bi DAC™ Degrader, is Active in a Subset of Multiple Myeloma Cell Line Models and Synergistic when Combined with Pomalidomide
BLOOD（2023）
关键词
Tumor Microenvironment
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要
BLOOD（2023）